Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Takeda and TAP sign promotion agreement for Amitiza

Feb. 28, 2007

New treatment options for hepatitis C described in recent patents

Feb. 27, 2007

Sebivo recommended for approval in E.U. for chronic hepatitis B

Feb. 26, 2007

Novel treatment options for gastrointestinal disorders reported in recent patents

Feb. 23, 2007

MIST-B02 shows promise in pilot pharmacokinetic study

Feb. 22, 2007

Recent Tibotec, Medivir and Valeant patents report novel anti-hepatitis agents

Feb. 22, 2007

Preclinical studies show CF-102 active against hepatitis B virus

Feb. 21, 2007

Combined erythromycin/metoclopramide therapy shows promise in feed intolerance

Feb. 19, 2007

Bavituximab shows signs of dose dependent antiviral activity in chronic HCV

Feb. 16, 2007

Phase II results suggest tetomilast is active in ulcerative colitis

Feb. 16, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...